Business Context and Reporting Period
This Form 6-K filing by Intercure Ltd. covers the month of August 2026. The report details a completed private placement offering (the "Offering") of securities to raise capital for working capital and facility rehabilitation.
Key Financial Metrics and Transaction Details
- Transaction Type: Private placement of 1,579,028 units.
- Unit Composition: One ordinary share and one warrant per unit.
- Purchase Price: $2.918 per unit.
- Warrant Terms: Exercisable for five years at $1.59 per share.
- Gross Proceeds: $5 million from external investors; approximately $2 million expected from CEO Alexander Rabinovich (subject to shareholder approval).
- Use of Proceeds: Working capital and rehabilitation of the Nir Oz facility of subsidiary Canndoc Ltd.
Material Changes and Corporate Actions
The primary material event is the completion of the Offering on August 25, 2026. A significant condition involves the participation of Mr. Alexander Rabinovich, the CEO and Chairman, who beneficially owns approximately 26% of outstanding shares. His participation requires shareholder approval, whereas other investors were not subject to this requirement. The filing does not provide comparative financial metrics such as revenue, profit, or cash flow for the period.
Outlook, Risks, and Contingencies
Management intends to utilize the raised funds for operational liquidity and specific asset rehabilitation. The filing includes a Safe Harbor statement noting that forward-looking statements regarding shareholder approval and the use of proceeds are subject to uncertainties. The securities were issued under exemptions (Section 4(a)(2) and Rule 903 of Regulation S) and are not registered under the Securities Act of 1933. Detailed risk factors are referenced in the Company's Form 20-F for the year ended December 31, 2025.
Investor Verification Checklist
- Confirm the status of shareholder approval for CEO Alexander Rabinovich's $2 million investment.
- Verify the timeline and budget for the rehabilitation of the Canndoc Ltd. Nir Oz facility.
- Review the full text of the Securities Purchase Agreement and Warrant forms (Exhibits 10.1 and 4.1) for specific covenants.
- Assess the dilution impact of the 1,579,028 new units and associated warrants on existing shareholders.